Biotech Firm Soars on Flu Shot Breakthrough, Injects 113% Gains

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today.

A new wave of viral threats is quietly building—and one under-the-radar biotech firm may be on the front lines.

While vaccination rates decline and old viruses like measles make a comeback, one experimental treatment is showing early promise across a wide range of high-risk infections… from RSV to influenza and even long COVID.

Early data suggests it could potentially target up to 90–95% of known human viruses. That’s not a typo.

With no approved treatments for some of these major threats—and a clinical-stage drug now entering preclinical measles testing—investors are starting to take notice.

It just hit a 6-month high. Broke through key technical levels. And it’s still trading at microcap levels.

This could be a chance to get in before the broader market catches on.

Click here to see the full report and company breakdown

Wall Street closed higher on Monday as dovish commentary on interest rates and fading uncertainty around U.S.-Iran tensions outweighed concerns about escalating conflict in the Middle East.

Omnicom (NYSE: OMC) has cleared a critical regulatory hurdle, with the U.S. Federal Trade Commission accepting a consent order that paves the way for its $13.5 billion acquisition of Interpublic.

This move positions Omnicom to reshape the advertising and media buying landscape, bringing together two giants in a big industry shake-up.

The FTC's approval comes with conditions designed to prevent Omnicom from coordinating or directing ad spending based on political or ideological views.

These restrictions aim to protect fair competition and media neutrality as the combined entity gains a significant market share.

This development matters deeply to investors.

For those who hold shares in Omnicom, the deal underscores the company's commitment to achieving long-term growth through strategic consolidation.

By expanding its scale and service offerings, Omnicom is positioning itself to compete more effectively in the rapidly evolving global advertising market.

The company's ability to navigate regulatory challenges also demonstrates its solid execution and risk management qualities, which are valued by the market.

For prospective investors evaluating Omnicom, this deal signals confidence in the company's future resilience in ad spending and its ability to deliver stronger value through expanded capabilities.

The integration of Interpublic's assets could unlock cost efficiencies and enhance client offerings at a time when digital transformation continues to reshape the industry.

Omnicom's successful pursuit of this deal reflects its intent to solidify leadership in an increasingly competitive and fragmented space, setting the stage for significant influence across global advertising markets.

This isn’t just politics—it’s a financial flashpoint.

As Trump and Musk go head-to-head, Wall Street is bracing for chaos: extreme volatility, tighter lending, and rising inflation.

In moments like this, only one asset has a history of surviving it all: gold.

Central banks and billionaires are already stockpiling it—before the fallout begins.

Now’s the time to learn how to legally convert retirement funds into physical gold—tax-free.

Get the FREE Gold IRA Survival Guide Today

Hims & Hers Health Inc. (NYSE: HIMS) is under scrutiny after Novo Nordisk severed ties due to concerns about how the telehealth company handled the sales of unapproved versions of Wegovy, a popular weight loss medication.

The breakup marks a major blow to Hims & Hers as it faces questions about its business practices and future in the weight-loss market.

Novo Nordisk cited patient safety concerns and what it described as “deceptive” marketing associated with cheaper knockoffs of Wegovy.

The drugmaker said Hims & Hers failed to follow laws designed to limit mass sales of compounded medications, ending a partnership meant to broaden access to approved treatments.

For existing shareholders, this development highlights a serious reputational and legal challenge.

The company’s business model, particularly in weight-loss care, is now under scrutiny.

Investors will need to watch how Hims & Hers manages growing regulatory attention and works to rebuild trust in its platform.

Those evaluating Hims & Hers as a potential investment may consider the rising risks associated with regulatory compliance and brand perception.

Maintaining market position amid tough competition and stricter oversight will depend on the firm’s ability to reassure both patients and partners.

Continuing to offer a range of treatments through its platform remains a company commitment.

Still, the end of this high-profile partnership will likely prompt a closer examination of how it balances innovation with compliance going forward.

This July, a little-known rule goes into effect—forcing Big Banks to rethink what qualifies as “real money.”

Surprisingly, they’re not betting on stocks, bonds, or even the U.S. dollar… they’re going all-in on physical gold.

According to Peter Schiff, it’s now “the only form of money trusted by the banking system.”

Investors tied to traditional accounts like IRAs or 401(k)s may be left behind.

But there’s still time to act.

Download the Free Gold Retirement Guide Before July

Goldman Sachs (NYSE: GS) has officially rolled out its artificial intelligence assistant company-wide.

The move marks a significant step in the bank’s commitment to leveraging technology to support its operations and employees.

The AI tool, called GS AI Assistant, aims to help staff summarize documents, draft content, and analyze data more quickly.

The assistant was already in use by about 10,000 employees ahead of the formal launch.

Goldman’s internal memo described the rollout as a key effort to boost productivity as the bank looks for more innovative ways to manage tasks that are often time-consuming.

The middle of this development highlights how Goldman is trying to stay competitive as large banks turn to AI to modernize.

For those holding shares in GS, this move demonstrates the firm’s clear intention to leverage new technology to enhance efficiency, an area that can support long-term profitability.

Those evaluating Goldman as a potential investment may view this as a sign of a company willing to invest in tools that could give it a competitive edge in both client service and internal operations.

By rolling out this AI tool, Goldman reinforces its position as a leader that adapts to the changing needs of technology in finance.

The firm’s strategy to utilize AI responsibly and effectively will be something investors will likely watch in the months ahead.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Cidara Therapeutics Inc [CDTX] $44.88 (+113.51%)

Cidara Therapeutics shares soared after the company reported positive Phase 2b trial results showing its experimental flu therapy, CD388, was up to 76% effective in preventing symptoms over 24 weeks.

Geospace Technologies [GEOS] $18.40 (+60.14%)

Geospace Technologies rose after institutional investors, including Grace & White and First Eagle, significantly increased their stakes in the company.

Spartannash Company [SPTN] $26.57 (+50.62%)

SpartanNash surged after agreeing to be acquired by C&S Wholesale Grocers in a $1.77 billion all-cash deal at a 52.5% premium.

Hims & Hers Health Inc [HIMS] $41.98 (-34.64%)

Hims & Hers stock plunged after Novo Nordisk terminated its partnership and accused the company of illegally selling compounded versions of its weight-loss drug, Wegovy.

Venture Global Inc [VG] $16.51 (-13.15%)

Venture Global shares slipped amid a string of analyst downgrades and price target cuts, including a new ‘Sell’ rating from Wall Street Zen.

Gdev Inc [GDEV] $16.37 (-11.01%)

GDEV stock fell following the announced departure of its Chief Operating Officer, triggering investor uncertainty about operational continuity.

The world may be sleepwalking into the next viral crisis.

With measles making a comeback, RSV cases rising, and long COVID still lingering… global health systems are under pressure.

But one clinical-stage biotech may have found a game-changing solution: a single antiviral compound designed to target a wide range of high-risk viruses—potentially 90–95% of known threats.

There are no approved treatments for RSV or measles today. Yet in early animal studies, this breakthrough candidate completely cleared RSV infections—and is now being tested against measles.

The stock has quietly surged past major technical resistance. The float is tight. The market cap is still tiny.

And the biotech space is seeing billions in investment as global health becomes a renewed priority.

Want to know why investors are paying attention now?

Click here to access the full breakdown

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.